top of page

Boustead client, ePallet, addresses food packaging shortage in Bloomberg News


Boustead Securities, LLC (“Boustead”) client, ePallet, a technology and logistics company that simplifies buying and selling wholesale food by the pallet, is featured in the Bloomberg article, "Pantry Buying Is So Hot There Aren’t Enough Cans."

Another consequence of the COVID-19 pandemic is consumers stocking up on pantry items, resulting in a shortage of cans and can labels. Companies like ePallet, are rushing to keep up with demand.

“There really is a shortage of product,” said James Kwon, the Chief Executive Officer and Co-founder of ePallet. “People aren’t buying based on brand or flavor, but based on availability.” (Bloomberg)

Many Americans are eating their meals at home and stocking up on pantry items as a way to save money and prepare for a potential second wave of the Coronavirus. “Regardless of if there is a second wave or not, the economic outcomes will be challenging people who are still out of jobs,” said Max Gold, also a cofounder of ePallet. “Everybody is prepared for the worst.” (Bloomberg) Sales for canned items continue to outpace last year. "In March and April, [Starkist] sales were up 120% from a year earlier. Now they’re trending at an annualized increase of about 30%, according to Andy Mecs, the company’s vice president of marketing and innovation... “At retail, it’s akin to toilet paper and paper towels,” Mecs said. “We’ve been running our factories at full speed trying to keep up with demand.” (Bloomberg)


Read the full Bloomberg article here.

 

About ePallet ePallet is a technology and logistics company that makes it easy and efficient for both vendors and buyers to buy and sell wholesale food by the pallet. ePallet offers real-time, delivered pricing, and all the information you need at your fingertips. For more information, please visit our website at www.epallet.com.  About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. Forward-Looking Statements This document contains forward-looking statements.  In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.


Boustead client, Rastegar Property Company, in GlobeSt article, "Austin Nabs Tesla Gigafactory Spot"


Boustead Securities, LLC (“Boustead”) client, Rastegar Property Company, a vertically integrated real estate company based in Austin, Texas, is featured in the GlobeSt article, "Austin Nabs Tesla Gigafactory Spot But Much More."

Ari Rastegar, founder and CEO of Rastegar Property Company, spoke with GlobeSt about Tesla's announcement to build the company's latest gigafactory in Austin, Texas. "This is the game changer of all game changers" Rastegar tells GlobeSt.com. "This is going to make Austin unworldly on the global stage.”

According to Elon Musk, "the newest Tesla factory will focus primarily on the company’s all-electric pickup vehicle, the Cybertruck, but also manufacture the automaker’s Semi, Model 3 and Model Y vehicles for the eastern half of North America."

“The profundity of Tesla moving to Austin is so much greater than just simply a company of Tesla’s status moving to Austin in an isolated incident,” says Rastegar. “When you take companies such as Google having their second largest office in the world, Apple with their 140-acre campus, Dell being in Round Rock, Oracle’s new major campus, Amazon’s acquisition in Whole Foods (being an Austin-based company), as well as Facebook, all of that together created this massive synergy for what Austin is becoming. Tesla adding the gigafactory is the linchpin. That’s the final moment where we now know that Austin is the next San Francisco.”


Tesla Global Headquarters In Austin?

Rastegar foresees more Austin news from Tesla: “We believe that they’ll eventually move their global headquarters as well after this $1.1 billion acquisition. We understand the corridor off of 130 in Del Valle very well as we own 50 acres about five minutes away from the site and have done extensive research on the area. It’s going to invigorate that entire corridor, bringing homes and jobs,” Rastegar tells GlobeSt.com.

“But what’s most interesting, is all the companies that support Tesla and all the ancillary mechanical parts that go into building the gigafactory products are what’s going to cause another huge surge in jobs and another huge surge in real estate prices in areas that normally didn’t have them. This is the game changer of all game changers. This is going to make Austin unworldly on the global stage.”

Read the full GlobeSt.com article here.

 

About Rastegar Property Company

Rastegar Property Company is a vertically-integrated real estate company that believes in putting investors first. This philosophy is founded on: building portfolios positioned to generate above market current income and maintain objectives of long-term capital appreciation; cultivating long-term relationships with investors, partners, and organizations; and utilizing the most up-to-date technology and data analysis available. For more information, please visit our website at www.rastegarproperty.com. 

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.

Forward-Looking Statements

This document contains forward-looking statements.  In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

Boustead Securities Client Nano-C Inc., Announces Signed Letter of Intent with Unify Pharmaceuticals

Boustead Securities Client, Nano-C, Inc., Announces Signed Letter of Intent with Unify Pharmaceuticals to Pursue Strategic Partnership for Parkinson’s and COVID-19 Indications


Nano-C’s Unique Chemistry is a Key Enabler for Potential Drug Efficacy

in Broad Range of Treatments



Boustead Securities, LLC (“Boustead”) client, Nano-C, Inc. (“Nano-C” or the “Company”), a leading producer of patented specialty active ingredients and formulations, announces a signed Letter of Intent (LOI) to pursue a strategic partnership with Unify Pharmaceuticals, a Vanderbilt University spinout co-founded by Dr. Laura Dugan (Vanderbilt, Washington University, Stanford, MIT). Unify is set to begin Phase 1 clinical trials this year for drug therapies for neurodegenerative disease as well as fast-track clinical trials for treatment of COVID-19.

Nano-C and Unify have had a growing and active business relationship for several years and are pleased to formalize their strategic partnership. As Unify’s chemistry partner, Nano-C will manage the scale up and synthesis of a functionalized fullerene identified as UP-1007, Unify’s active pharmaceutical ingredient (API), at an exacting cGMP standard. Nano-C and Unify intend to execute a Contract Manufacturing and Supply Agreement covering the preparation for and completion of Phase I and fast-track clinical trials.

Dr. Dugan has studied the therapeutic properties of functionalized fullerenes for over 20 years and has published numerous scientific papers on the potential benefits of these unique APIs on neurodegenerative disease including Parkinson’s and Alzheimer’s. Pre-clinical trials showed marked efficacy on primates afflicted with Parkinson’s Disease, with statistically significant differences appearing after just 30 days vs the control with no toxicity over the course of the trial. Data from Dr. Dugan’s research is being leveraged for a possible COVID-19 drug therapy.


Fullerenes are small molecules that can be customized for use in a wide range of therapeutic applications. Their versatility stems from their fundamental molecular properties and by applying functional chemistry to their surface, they become a true molecular platform that potentially enables strong anti-viral and anti-inflammatory properties to affect a new class of therapeutics.

Nano-C and Unify are in the process of negotiating a term sheet to pursue a strategic alliance. This strategic partnership marks Nano-C’s market expansion into biopharmaceuticals and gives Unify access to Nano-C’s leading-edge organic chemists for the optimization of UP-1007 and next generation APIs, and at the volumes and quality required during the clinical trial phase and into commercialization.



This press release is not a solicitation or offer to buy or sell securities. For illustrative purposes only. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.

 

About Nano-C, Inc. Nano-C is a leading innovator and manufacturer in the chemistry of nanostructured carbon, including fullerenes, carbon nanotubes (CNT), and their chemical derivatives. Nano-C is focused on fundamental technology trends: the roll-out of 5G, connectivity driven by the Internet of Things, the race to extend Moore’s Law, the move to address climate change through sustainable energy generation and now healthcare.  Proprietary materials produced by Nano-C are critical links in the value chain for next-generation electronics, sensors, semiconductor manufacturing and biopharmaceuticals. Nano-C’s advanced materials and molecular platform encompasses a portfolio of unique solutions protected by over 150 global patents across 46 patent families. Through its patented products and processes, and its distinct competencies in the chemistry of these materials, Nano-C is enabling a revolution in device design, manufacture, and performance, and it is committed to their responsible development and use. For more information, please visit our website at www.nano-c.com.  About Unify Pharmaceuticals Unify Pharmaceuticals is a biotech company utilizing the latest scientific discoveries to develop drugs targeting neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s and Strokes. The company is the culmination of over 20 years’ research into UP-1007 and related molecules.  UP-1007 is the first-in-class water-soluble fullerene that has been shown to successfully address the underlying causes of Parkinson’s and other diseases involving oxidative damage. For more information please visit www.unifypharma.com. About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. About Sutter Securities Group, Inc. Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com. Forward-Looking Statements This document contains forward-looking statements.  In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing.  We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us.  Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities.  You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.  In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business.  These and other factors may cause our actual results to differ materially from any forward-looking statement.  Forward-looking statements are only predictions.  The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us.  We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

bottom of page